Related Experiment Video
Updated: Feb 17, 2026

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma
Elisa Lazzari1, Phoebe K Mondala1, Nathaniel Delos Santos1
1Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92037, USA.
Abstract:
Despite novel therapies, relapse of multiple myeloma (MM) is virtually inevitable. Amplification of chromosome 1q, which harbors the inflammation-responsive RNA editase adenosine deaminase acting on RNA (ADAR)1 gene, occurs in 30-50% of MM patients and portends a poor prognosis. Since adenosine-to-inosine RNA editing has recently emerged as a driver of cancer progression, genomic amplification combined with inflammatory cytokine activation of ADAR1 could stimulate MM progression and therapeutic resistance. Here, we report that high ADAR1 RNA expression correlates with reduced patient survival rates in the MMRF CoMMpass data set. Expression of wild-type, but not mutant, ADAR1 enhances Alu-dependent editing and transcriptional activity of GLI1, a Hedgehog (Hh) pathway transcriptional activator and self-renewal agonist, and promotes immunomodulatory drug resistance in vitro. Finally, ADAR1 knockdown reduces regeneration of high-risk MM in serially transplantable patient-derived xenografts. These data demonstrate that ADAR1 promotes malignant regeneration of MM and if selectively inhibited may obviate progression and relapse.
Insights
Amplification of the ADAR1 gene promotes multiple myeloma (MM) progression and resistance to treatment. Inhibiting ADAR1 may prevent MM relapse and disease advancement.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Multiple myeloma (MM) frequently relapses despite new treatments.
- Chromosome 1q amplification, including the ADAR1 gene, is common in MM and linked to poor outcomes.
- RNA editing by adenosine deaminase acting on RNA (ADAR)1 is implicated in cancer progression.
Purpose of the Study:
- To investigate the role of ADAR1 in MM progression and therapeutic resistance.
- To determine the correlation between ADAR1 expression and patient survival.
- To assess the impact of ADAR1 inhibition on MM regeneration.
Main Methods:
- Analysis of ADAR1 RNA expression in the MMRF CoMMpass data set.
- In vitro experiments assessing the effect of wild-type and mutant ADAR1 on GLI1 activity and drug resistance.
- In vivo studies using patient-derived xenografts to evaluate ADAR1 knockdown effects on MM regeneration.
Main Results:
- High ADAR1 RNA expression significantly correlates with reduced survival in MM patients.
- Wild-type ADAR1 enhances GLI1 transcription and promotes resistance to immunomodulatory drugs.
- ADAR1 knockdown reduces the regeneration of high-risk MM in xenograft models.
Conclusions:
- ADAR1 promotes MM malignant regeneration and therapeutic resistance.
- Targeting ADAR1 may offer a novel strategy to prevent MM progression and relapse.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Related Concept Videos
RNA Editing
Abnormal Proliferation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Non-LTR Retrotransposons
Leaky Scanning
Induced Pluripotent Stem Cells
Somatic...